Rigel Pharmaceuticals Inc
A South San Francisco biotechnology company that develops and sells prescription medicines for blood disorders and cancer. Its FDA-approved drugs include Tavalisse for immune thrombocytopenia (a low blood-platelet condition) and Rezlidhia for a form of acute myeloid leukemia. Founded in 1996, the company shares its name with Rigel, a brilliant blue star in the Orion constellation whose Arabic name means "the foot of the giant."
Granted 666.2K · Sold 62.2K
Granted 25.0K
Granted 259.2K · Sold 16.4K
Granted 248.1K · Sold 18.4K
Granted 248.2K · Sold 2.8K
Granted 38.6K
Granted 37.3K · Sold 4.0K
Granted 33.3K
Granted 33.3K
Granted 33.3K
Granted 33.3K · Sold 5.0K
Granted 7.0K
Granted 5.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rodriguez Raul RCEO, President, Director · 18 transactions | -83.4% | 279.6K | 666.2K | — | 62.2K |
| Kotzin Brian L.Director · 1 transaction | +33.3% | 100.0Kas of May 2024 | 25.0K | — | — |
| Schorno Dean LEVP & Chief Financial Officer · 15 transactions | -59.9% | 78.8K | 259.2K | — | 16.4K |
| Santos David AEVP, Chief Commercial Officer · 10 transactions | -57.1% | 62.0K | 248.1K | — | 18.4K |
| Furey Raymond J.EVP, GC, CCO & Corp Sec · 8 transactions | — | 50.9K | 248.2K | — | 2.8K |
| Rojkjaer LisaEVP, Chief Medical Officer · 4 transactions | — | 34.0K | 38.6K | — | — |
| Moos Walter HDirector · 5 transactions | -76.1% | 18.5K | 37.3K | — | 4.0K |
| Lapointe Anthony GreggDirector · 3 transactions | -75.7% | 18.3K | 33.3K | — | — |
| Wasman JaneDirector · 3 transactions | -75.7% | 18.3K | 33.3K | — | — |
| Hannah Alison L.Director · 3 transactions | -70.9% | 16.4K | 33.3K | — | — |
| Ali-Jackson KamilDirector · 5 transactions | -76.9% | 10.1K | 33.3K | — | 5.0K |
| Frohlich Mark WDirector · 2 transactions | — | 7.0K | 7.0K | — | — |
| Miller Michael PatrickDirector · 1 transaction | — | 5.9K | 5.8K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -108.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.